Oesophageal Doppler Features Strongly in Updated Cancer Surgery Guidance

The UK’s National Institute for Health and Care Excellence (NICE) has updated its guidance for practitioners in the management of colorectal cancer. NICE publishes it’s so-called “pathways” in order to bring together everything NICE says on a topic in an interactive flowchart. The revised treatment pathway, published on June 6th 2019 is entitled Managing Local Colorectal Tumours and specifically recommends using Deltex’s oesophageal Doppler monitoring (ODM) during tumour resection surgery.

CardioQ ODM was included in the 2011 NICE guidance, which can be found here. That document said CardioQ-ODM should be considered for use in patients undergoing major or high-risk surgery or other surgical patients in whom a clinician would consider using invasive cardiovascular monitoring. It is referenced in the newly updated Colorectal Tumour pathway, describing the case for its adoption as being “supported by the evidence.”

The guidance cites a reduction in post-operative complications, use of central venous catheters and in-hospital stay (with no increase in the rate of re-admission or repeat surgery) compared with conventional clinical assessment with or without invasive cardiovascular monitoring. It also talks of the cost saving per patient when the CardioQ-ODM is used instead of a central venous catheter in the peri-operative period.

Deltex CEO Andy Mears says of the new guidance: “The benefits of managing a patient’s haemodynamic status accurately and in real time are absolutely clear and supported by the most robust clinical evidence. We’re delighted that once again our unique technology has been recognised by such a respected organisation.”